Mirum Pharmaceuticals Inc...
43.33
-0.67 (-1.52%)
At close: Jan 14, 2025, 3:59 PM
43.32
-0.02%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 41
Market Cap 2.08B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.08
PE Ratio (ttm) -20.83
Forward PE n/a
Analyst Buy
Ask 46.92
Volume 773,537
Avg. Volume (20D) 376,100
Open 44.87
Previous Close 44.00
Day's Range 43.20 - 45.10
52-Week Range 23.14 - 48.89
Beta undefined

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment o...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 2019
Employees 311
Stock Exchange NASDAQ
Ticker Symbol MIRM

Analyst Forecast

According to 10 analyst ratings, the average rating for MIRM stock is "Buy." The 12-month stock price forecast is $63, which is an increase of 45.40% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Mirum Pharmaceuticals Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $86.85M, reflecting a 24.87% YoY growth and earnings per share of -0.34, making a -48.48% decrease YoY.
7 months ago · Source
+27.31%
Mirum Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription
10 months ago · Source
+1.44%
Mirum Pharmaceuticals shares are trading higher after the company announced that the FDA approved LIVMARLI oral solution for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $45 to $58.